CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

RegulatoryapprovedTECVAYLIPositive

AI Analysis

Summary

The EMA's CHMP recommended approval of Johnson & Johnson's TECVAYLI (teclistamab) for an indication extension in relapsed/refractory multiple myeloma patients with at least one prior therapy.

Outcome Details

CHMP recommended approval for indication extension in relapsed/refractory multiple myeloma

Importance:7/10

Sentiment:

0.80

EMACHMPindication extensionmultiple myelomaregulatory approval

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 18, 2026 11:00 AM

Read Original